Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information.
Innovators in Reproductive Health
Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information.
Ixchelsis is pleased to announce that two abstracts relating to the results of the proof of concept trial (PEPIX) of IX-01 in men with lifelong premature ejaculation were accepted … [Read More...]
Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information. … [Read More...]
Following the positive proof-of-concept data released in 2016, Ixchelsis is pleased to announce the start of the Phase II B dose range-finding study for IX-01 in February 2017. The … [Read More...]
IXCHELSIS Ltd
DISCOVERY PARK HOUSE
RAMSGATE ROAD
SANDWICH
KENT
CT13 9NJ
UNITED KINGDOM
Registered in England
Company Registration Number 07719191
VAT Number 171 4965 89
> Website Terms & Conditions
> Privacy Policy
This website uses cookies.
> View our Cookie Policy
Web Site Developed by VinceWEBDESIGN · © 2023 · Ixchelsis Ltd · Admin